基于计算机断层扫描血管造影的颈动脉斑块-RADS分类、复发性血管事件及秋水仙碱效应:CONVINCE随机试验的影像学子研究
本研究为CONVINCE试验的事后观察性队列分析,纳入517例非心源性栓塞性卒中/短暂性脑缺血发作患者,评估基于CTA的颈动脉斑块-RADS分类与复发性缺血事件的关联。结果显示斑块-RADS≥3与复发性同侧卒中、任何卒中/TIA及主要不良心血管事件独立相关,且秋水仙碱对主要不良心血管事件的疗效在斑块-RADS≥3患者中更显著。
要点
- 斑块-RADS≥3与复发性同侧卒中独立相关(调整后HR 7.80,95%CI 1.55–39.30)。
- 斑块-RADS≥3与任何卒中/TIA独立相关(调整后HR 3.94,95%CI 1.68–9.24)。
- 秋水仙碱对MACE的疗效在斑块-RADS≥3患者中更显著(HR 0.35,95%CI 0.15–0.82)。
核心结论
- 在索引缺血性卒中同侧颈内动脉中,基于CTA的颈动脉斑块-RADS与复发性缺血性卒中及心血管事件相关。
- 秋水仙碱的治疗效应在不同斑块-RADS分类(<3 vs ≥3)间存在差异,提示斑块易损性评估可能有助于细化抗炎治疗的患者选择。
研究设计与样本
- CONVINCE试验(非心源性栓塞性卒中中秋水仙碱预防血管炎症)的事后观察性队列分析,纳入来自13个欧洲中心的517例参与者。
- 分析510例患者(中位年龄67.0岁;男性72.2%)的966条颈内动脉,其中321条为索引缺血性卒中同侧颈内动脉。
- 使用多因素Cox比例风险模型评估斑块-RADS与复发性同侧卒中、任何卒中/TIA及主要不良心血管事件的关联,斑块-RADS分别按二分类(<3 vs ≥3)和序数(每增加1分)变量分析。
- 通过交互作用和分层分析评估秋水仙碱治疗效应是否因斑块-RADS分类而异。
主要发现
- 在中位35.7个月随访期间,321条索引卒中同侧颈内动脉中发生12例复发性同侧卒中、32例任何卒中/TIA和37例主要不良心血管事件。
- 调整年龄、性别和心血管危险因素后,斑块-RADS≥3(n=140)与复发性同侧卒中独立相关(调整后HR 7.80,95%CI 1.55–39.30;P=0.01)。
- 斑块-RADS≥3与任何卒中/TIA独立相关(调整后HR 3.94,95%CI 1.68–9.24;P<0.01)。
- 斑块-RADS≥3与主要不良心血管事件独立相关(调整后HR 2.52,95%CI 1.19–5.34;P=0.02)。
- 秋水仙碱治疗与主要不良心血管事件存在显著交互作用(P=0.047),斑块-RADS≥3患者中获益更大(HR 0.35,95%CI 0.15–0.82)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「局限性」,故未列出该栏;全文请点「阅读原文」。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Stroke, Ahead of Print. BACKGROUND:The carotid Plaque Reporting and Data System (Plaque-RADS) provides a standardized framework for evaluating plaque morphology, but prospective validation remains limited. We investigated the association between computed tomography angiography-based Plaque-RADS categories and subsequent ischemic events in patients with noncardioembolic stroke/transient ischemic attack, from a completed clinical trial of colchicine. Second, we assessed whether the effect of colchicine differed by Plaque-RADS risk classification.METHODS:We conducted a posthoc observational cohort analysis of 517 participants in the CONVINCE trial (Colchicine for Prevention of Vascular Inflammation in Non-CardioEmbolic Stroke) from 13 European sites. Associations between Plaque-RADS and recurrent ipsilateral stroke, any stroke/transient ischemic attack, and major adverse cardiovascular events were assessed using multivariable Cox proportional hazards models. Plaque-RADS was analyzed as both dichotomized (<3 versus ≥3) and ordinal (per 1-point increase) variables. Treatment effects were assessed by Plaque-RADS classification using interaction and stratified analyses.RESULTS:A total of 510 patients (median age, 67.0 years; 72.2% male) with 966 internal carotid arteries were included. Among 321 internal carotid arteries ipsilateral to the index ischemic stroke, 12 recurrent ipsilateral strokes, 32 any strokes/transient ischemic attacks, and 37 major adverse cardiovascular events occurred over a median 35.7-month follow-up. Plaque-RADS ≥3 (n=140) was independently associated with recurrent ipsilateral stroke (adjusted hazard ratio, 7.80 [95% CI, 1.55–39.30];P=0.01), any stroke/transient ischemic attack (adjusted hazard ratio, 3.94 [95% CI, 1.68–9.24];P<0.01), and major adverse cardiovascular events (adjusted hazard ratio, 2.52 [95% CI, 1.19–5.34];P=0.02) after adjustment for age, sex and cardiovascular risk factors. A significant interaction with colchicine treatment was observed for major adverse cardiovascular events (P=0.047), with greater benefit among patients with Plaque-RADS scores ≥3 (hazard ratio, 0.35 [95% CI, 0.15–0.82]).CONCLUSIONS:In internal carotid arteries ipsilateral to the index ischemic stroke, computed tomography angiography-based carotid Plaque-RADS was associated with recurrent ischemic stroke and cardiovascular events. Importantly, treatment effects of colchicine varied across Plaque-RADS classification (<3 versus ≥3), suggesting that plaque vulnerability assessment may help refine patient selection for anti-inflammatory therapy beyond stenosis-based classification. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT02898610.
引用
- Stroke:Computed-Tomography Angiography-Based Carotid Plaque-RADS, Recurrent Vascular Events, and the Effect of Colchicine: An Imaging Substudy of the CONVINCE Randomized Trial
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。